Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Human Papillomavirus
79%
HPV16
70%
Human Papillomavirus Vaccine
63%
Human Papillomavirus Types
31%
High-risk Human Papillomavirus (HR-HPV)
31%
HPV31
31%
HPV6
30%
Sexually Active
27%
High Coverage
27%
Vaccine Strain
24%
Vaccination
23%
Immunization
22%
Human Papillomavirus Prevalence
19%
Vaccination Program
18%
Cervarix
17%
Type-specific
16%
Human Papillomavirus DNA
16%
Gardasil
16%
AS04
16%
Protective Effect
16%
Cross-protective
16%
Vaccination Coverage
15%
Antibody Level
14%
Natural Infection
14%
Non-vaccine Type
14%
HPV18
13%
Quadrivalent
13%
Cervical Screening
12%
Antibody Binding Assay
10%
Neutralizing Antibodies
10%
Cross-protection
10%
Seropositivity
10%
Serostatus
10%
World Health Organization
10%
HPV-45
9%
Young Female
9%
Probability Sample Survey
9%
Young Women
9%
Chlamydia Screening
9%
Anogenital
8%
DNA Detection
8%
Vaccination Strategy
8%
Probability Survey
8%
EPub
8%
Ethnically Diverse
8%
Cervix
8%
Circumcision
8%
Cisgender
8%
HPV11
8%
National Probability Sample
8%
Immunology and Microbiology
Wart Virus
100%
Human Papillomavirus Type 16
48%
Prevalence
35%
Cervarix
28%
Human Papillomavirus Type 31
27%
Infection
24%
Infectious Disease
24%
Human Papillomavirus Type 6
23%
Capsid
19%
Human Papillomavirus Type 58
16%
Lineages
16%
Human Papillomavirus Type 18
12%
Antigen
11%
Antigen Binding
11%
Antibody Response
11%
Neutralizing Antibody
10%
Human Papillomavirus Type 52
9%
Monoclonal Antibody
9%
Seropositivity
9%
Human Immunodeficiency Virus
9%
Antigenicity
9%
Human Papillomavirus Type 45
9%
Sexual Health
9%
Human Papillomavirus Type 33
8%
Cross Protection
8%
Binding Antibody
8%
Neisseria gonorrhoeae
8%
Chlamydia Trachomatis
8%
Nucleic Acid Amplification
8%
Virus-Like Particle
8%
Human Papillomavirus Type 11
8%
Dyskaryosis
8%
Serology
6%
